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Abstract 
Purpose: Although increased oxidative stress is a major component of diabetic hypertensive cardiomyopathy, 
research into the effects of antioxidants on cardiac remodeling remains scarce. The actions of antioxidant apoc‑
ynin include inhibiting reactive oxygen species (ROS) generation by nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases and ROS scavenging. We evaluated the effects of apocynin on cardiac remodeling in spontane‑
ously hypertensive rats (SHR) with diabetes mellitus (DM).
Methods: Male SHR were divided into four groups: control (SHR, n = 16); SHR treated with apocynin (SHR‑APO; 
16 mg/kg/day, added to drinking water; n = 16); diabetic SHR (SHR‑DM, n = 13); and SHR‑DM treated with apocynin 
(SHR‑DM‑APO, n = 14), for eight weeks. DM was induced by streptozotocin (40 mg/kg, single dose). Statistical ana‑
lyzes: ANOVA and Tukey or Mann–Whitney.
Results: Echocardiogram in diabetic groups showed higher left ventricular and left atrium diameters indexed for 
body weight, and higher isovolumetric relaxation time than normoglycemic rats; systolic function did not differ 
between groups. Isolated papillary muscle showed impaired contractile and relaxation function in diabetic groups. 
Developed tension was lower in SHR‑APO than SHR. Myocardial hydroxyproline concentration was higher in SHR‑
DM than SHR, interstitial collagen fraction was higher in SHR‑DM‑APO than SHR‑APO, and type III collagen protein 
expression was lower in SHR‑DM and SHR‑DM‑APO than their controls. Type I collagen and lysyl oxidase expression 
did not differ between groups. Apocynin did not change collagen tissue. Myocardial lipid hydroperoxide concentra‑
tion was higher in SHR‑DM than SHR and SHR‑DM‑APO. Glutathione peroxidase activity was lower and catalase higher 
in SHR‑DM than SHR. Apocynin attenuated antioxidant enzyme activity changes in SHR‑DM‑APO. Advanced glycation 
end‑products and NADPH oxidase activity did not differ between groups.
Conclusion: Apocynin reduces oxidative stress independently of NADPH oxidase activity and does not change 
ventricular or myocardial function in spontaneously hypertensive rats with diabetes mellitus. The apocynin‑induced 
myocardial functional impairment in SHR shows that apocynin actions need to be clarified during sustained chronic 
pressure overload.
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Background
Systemic arterial hypertension and diabetes mellitus 
(DM) represent two important risk factors for cardio-
vascular disease, the leading cause of morbidity and 
mortality in the world [1, 2]. The coexistence of arte-
rial hypertension and diabetes is commonly observed in 
adults and has been associated with a higher risk of car-
diovascular events [1–3]. In the heart, the combination of 
DM and hypertension, also known as diabetic hyperten-
sive cardiomyopathy leads to more extensive structural 
and functional cardiac changes than either condition 
alone [4–6]. However, the physiopathology of diabetes 
and hypertension-induced cardiac disease is not com-
pletely clear. Diabetes in hypertensive rodents impairs 
cardiac remodeling by exacerbating fibrosis, inflamma-
tion, microvascular changes, and oxidative stress result-
ing in intensified myocardial and cardiac dysfunction and 
increased mortality rate [5–11].
One of the major components of diabetic hypertensive 
cardiomyopathy is an increase in oxidative stress [5, 12, 
13]. The term oxidative stress refers to disturbance in 
redox hemostasis occurring when reactive oxygen spe-
cies (ROS) production exceeds their degradation by anti-
oxidant defenses [14]. In diabetes, oxidative stress can be 
induced by hyperglycemia, hyperlipidemia, and inflam-
mation. Antioxidants have been extensively evaluated 
for their potential to prevent or treat diabetic complica-
tions [15, 16]; however, research into the effects of anti-
oxidants on cardiac remodeling remains scarce [17, 18].
Apocynin, a constituent of root extracts of the medici-
nal herb Picrorhiza kurroa [19], has been used in exper-
imental studies as an antioxidant agent. Its actions 
include inhibiting ROS generation by the nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidases and 
ROS scavenging [14, 20, 21]. NADPH oxidases produce 
ROS as their primary function and can be involved in 
the pathophysiology of cardiac diseases [14, 22–24]. As 
hyperglycemia increases NADPH oxidase activity [23–
25], administration of its inhibitors has been tested in 
diabetic cardiomiopathy [26–29]. Studies performed in 
rodents with streptozotocin-induced DM have shown 
that NADPH oxidase activity is increased in DM [30]. 
Furthermore, inhibition of NADPH oxidase by apocynin 
alleviated myocardial contractile dysfunction in DM [28, 
31, 32]. However, few studies have analyzed the effects of 
apocynin in diabetic and hypertensive animals [33], and 
none in cardiac remodeling. Despite the potential ben-
efits of apocynin in oxidative stress, its effects are not 
completely understood and even pro-oxidant action has 
been reported in some experimental models [34, 35]. In 
this study, we evaluated the influence of apocynin on car-




Seven-month-old male spontaneously hypertensive rats 
(SHR) were purchased from the Multidisciplinary Center 
for Biological Investigation in Laboratory Animals Sci-
ence, State University of Campinas, SP, Brazil. All ani-
mals were housed in a room under temperature control 
at 23 °C and kept on a 12-h light/dark cycle. Commercial 
chow and water were supplied ad libitum. The rats were 
assigned into four groups: control SHR (n  =  16); SHR 
treated with apocynin (SHR-APO, n = 16); diabetic SHR 
(SHR-DM, n = 18); and diabetic SHR treated with apoc-
ynin (SHR-DM-APO, n = 19).
Diabetes was induced by intraperitoneal injection of 
streptozotocin (Sigma, St. Louis, MO, USA) at 40 mg/kg 
body weight diluted in 0.01 M citrate buffer pH 4.5 [36]. 
Control groups received an intraperitoneal injection of 
vehicle only. As the rats received only one moderate dose 
of streptozotocin, sucrose administration was not neces-
sary to avoid hypoglycemia caused by sudden release of 
insulin due to massive islet β-cells necrosis [37]. Seven 
days after streptozotocin administration, blood glucose 
was measured by glucometer (Advantage®). Only rats 
with glycemia >220 mg/dL were considered diabetic and 
included in the study [5, 36]. Apocynin (Sigma, St. Louis, 
MO, USA) was added to drinking water at a dosage of 
16 mg/kg/day for 8 weeks [38]. Water consumption was 
measured daily and body weight weekly. Systolic arterial 
pressure was measured before streptozotocin injection 
and at the end of experiment by tail-cuff method using a 
model 709-0610 electro-sphygmomanometer (Narco Bio-
System®, International Biomedical Inc., USA).
Echocardiographic study
Echocardiographic evaluation was performed before 
diabetes induction and at the end of the experimental 
period. We used a commercially available echocardio-
graph (General Electric Medical Systems, Vivid S6, Tirat 
Carmel, Israel) equipped with a 5–11.5  MHz multifre-
quency probe, as previously described [39–41]. Rats were 
anesthetized by intramuscular injection of a mixture 
of ketamine (50  mg/kg) and xylazine (0.5  mg/kg). Two-
dimensionally guided M-mode images were obtained 
from short-axis views of the left ventricle (LV) just below 
the tip of the mitral-valve leaflets, and at the level of the 
aortic valve and left atrium. M-mode images were printed 
on a thermal printer (Sony UP-890MD) at a sweep speed 
of 100 mm/s. All LV structures were manually measured 
by the same observer (KO). Values obtained were the 
mean of at least five cardiac cycles on M-mode tracings. 
The following structural variables were measured: left 
atrium diameter (LA), LV diastolic diameter (LVDD), and 
LV diastolic and systolic posterior wall thickness (PWT 
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and SWT, respectively). LV relative wall thickness (RWT) 
was calculated using the formula  2  ×  PWT/LVDD. LV 
mass was calculated using the formula [(LVDD + PWT 
+ SWT)3 − (LVDD)3] × 1.04. LV function was assessed 
by the following parameters: midwall fractional shorten-
ing (MFS), tissue Doppler imaging (TDI) of mitral annu-
lus systolic velocity (S’), myocardial performance index 
(Tei index), early and late diastolic mitral inflow veloci-
ties (E and A waves), E/A ratio, isovolumetric relaxation 
time (IVRT), TDI of early mitral annulus diastolic veloc-
ity (E’), and E/E’ ratio. Tissue Doppler variables (S’ and E’) 
were measured at the septal and lateral walls, and average 
values presented [42].
Myocardial functional evaluation
At the end of the experimental period, myocardial con-
tractile performance was evaluated in isolated LV papil-
lary muscle preparation as previously described [43, 44]. 
Rats were anesthetized (pentobarbital sodium, 50  mg/
kg, intraperitoneally) and decapitated. Hearts were 
quickly removed and placed in oxygenated Krebs–Hense-
leit solution at 28  °C. LV anterior or posterior papillary 
muscle was dissected free, mounted between two spring 
clips, and placed vertically in a chamber containing 
Krebs–Henseleit solution at 28 °C and oxygenated with a 
mixture of 95 % O2 and 5 % CO2 (pH 7.38). The composi-
tion of the Krebs–Henseleit solution in mM was as fol-
lows: 118.5 NaCl, 4.69 KCl, 1.25 CaCl2, 1.16 MgSO4, 1.18 
KH2PO4, 5.50 glucose, and 25.88 NaHCO3. The spring 
clips were attached to a Kyowa model 120T-20B force 
transducer and a lever system, which allowed for mus-
cle length adjustment. Preparations were stimulated 12 
times/min at a voltage 10 % above threshold.
After a 60  min period, during which the prepara-
tions were permitted to shorten while carrying light 
loads, muscles were loaded to contract isometrically and 
stretched to the apices of their length-tension curves. 
After a 5  min period, during which preparations per-
formed isotonic contractions, muscles were again placed 
under isometric conditions, and the apex of the length-
tension curve (Lmax) was determined. A 15  min period 
of stable isometric contraction was imposed prior to the 
experimental period. One isometric contraction was then 
recorded for later analysis.
The following parameters were measured from the iso-
metric contraction: peak developed tension (DT), resting 
tension (RT), time to peak tension (TPT), maximum ten-
sion development rate (+dT/dt), and maximum tension 
decline rate (−dT/dt). To evaluate myocardial contractile 
reserve, papillary muscle mechanical performance was 
evaluated after the following positive inotropic stimu-
lation: 30  s post-rest contraction, extracellular Ca2+ 
concentration increase to 2.5 mM, and β-adrenergic ago-
nist isoproterenol (10−6 M) addition to the nutrient solu-
tion [45]. Papillary muscle cross-sectional area (CSA) 
was calculated from muscle weight and length by assum-
ing cylindrical uniformity and a specific gravity of 1.0. All 
force data were normalized for muscle CSA.
Histologic analysis
Transverse LV sections were fixed in 10 % buffered for-
malin and embedded in paraffin. Sections  (5  µm thick) 
were stained with hematoxylin–eosin and collagen-spe-
cific stain picrosirius red (Sirius red F3BA in aqueous 
saturated picric acid) [46]. In at least 50 myocytes from 
each LV, where the nucleus could clearly be identified, 
the smallest transverse diameters were measured [47]. 
On average, 20 microscopic fields were used to quan-
tify interstitial collagen fraction. Perivascular collagen 
was excluded from this analysis [48]. Measurements 
were performed using a Leica microscope (magnifica-
tion 40×) attached to a video camera and connected 
to a computer equipped with image analysis software 
(Image-Pro Plus 3.0, Media Cybernetics, Silver Spring, 
MD, USA).
Myocardial hydroxyproline concentration
Hydroxyproline concentration was measured in LV to 
estimate myocardial collagen content [49]. Tissue was 
dried using a Speedvac Concentrator (SC 100) attached 
to a refrigerated condensation trap (TRL 100) and vac-
uum pump (VP 100, Savant Instruments, Inc., Farm-
ingdale, NY, USA). Dry tissue weight was measured and 
samples were hydrolyzed overnight at 100  °C with 6  N 
HCl (1  mL/10  mg dry tissue). An aliquot of the hydro-
lysate (50 μL) was transferred to an eppendorf tube and 
dried in the speedvac concentrator. One milliliter of 
deionized water was added and the sample transferred 
to a tube with a teflon screw cap. One milliliter of potas-
sium borate buffer (pH 8.7) was added to maintain con-
stant pH and the sample was oxidized with 0.3  mL of 
chloramine T solution at room temperature for 20 min. 
The addition of 1 mL of 3.6 M/L sodium thiosulfate with 
thorough mixing for 10 s stopped the oxidative process. 
The solution was saturated with 1.5  g KCl. The tubes 
were heated in boiling water for 20 min. After cooling to 
room temperature, the aqueous layer was extracted with 
2.5  mL of toluene. One and a half milliliters of toluene 
extract were transferred to a 12 × 75 mm test tube. Then 
0.6 mL of Ehrlich’s reagent was added and color allowed 
to develop for 30  min. Absorbance was read at 565  nm 
against a reagent blank. Deionized water and 20  μg/mL 
hydroxyproline were used as the blank and standard, 
respectively.
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Western blotting analysis
Protein expression of type I (Santa Cruz Biotechnology 
Inc., Santa Cruz, CA, USA, col1a1, sc-8784-r) and type 
III collagen (Abcam, Cambridge, UK, col3a1, ab6310) 
and lysil oxidase (Abcam, LOX1, ab60178) was analyzed 
by Western blot as previously described [50, 51]. Samples 
were separated on polyacrylamide gel and then trans-
ferred to a nitrocellulose membrane. After blockage, the 
membrane was incubated with the primary antibod-
ies overnight at 4  °C. The membrane was then washed 
with PBS and Tween 20 and incubated with secondary 
peroxidase-conjugated antibodies (Santa Cuz Biotech-
nology, anti-mouse, sc-2005, and anti-rabbit, sc-2004) 
for 90  min at room temperature. ECL western blotting 
substrate (Pierce Protein Research Products, Rockford, 
USA) was used to detect bound antibodies. The mem-
brane was then stripped (Restore Western Blot Stripping 
Buffer, Pierce Protein Research Products, Rockford, USA) 
to remove antibodies. After blockage, membrane was 
incubated with anti-GAPDH antibody (Santa Cruz Bio-
technology, GAPDH 6C5 sc-32233). Protein levels were 
normalized to GAPDH.
Myocardial oxidative stress evaluation
Frozen left ventricle myocardium (∼200 mg) was homog-
enized in phosphate buffer (0.1  M) pH 7.4 and cen-
trifuged at 12,000g for 15  min at 4  °C. The supernatant 
was assayed for total protein, lipid hydroperoxide, and 
anti-oxidant enzyme activity [52]. Lipid hydroperoxide 
concentration was determined in a medium containing 
methanol 90  % (v/v), 250  μM ammonium ferrous sul-
fate, 100  μM xylenol orange, 25  mM sulfuric acid, and 
4 mM butylated hydroxytoluene. The solution was incu-
bated for 30  min at room temperature and measure-
ment was performed at 560 nm. Glutathione peroxidase 
(GSH-Px, E.C.1.11.1.9) was assayed using 0.15  M phos-
phate buffer, pH 7.0, containing 5  mM EDTA, 0.1  mL 
of 0.0084 M NADPH, 4 μg of GSSG-reductase, 1.125 M 
sodium azide, and 0.15  M glutathione reduced form 
(GSH) in a total volume of 0.3 mL. Superoxide dismutase 
(SOD, E.C.1.15.1.1.) activity was determined based on 
its ability to inhibit reduction of nitroblue tetrazolium, 
in a medium containing 50  mM phosphate buffer pH 
7.4, 0.1 mM EDTA, 50 μM nitroblue tetrazolium, 78 μM 
NADH, and 3.3  μM phenazine methosulfate. One unit 
of SOD was defined as the amount of protein needed to 
decrease the reference rate to 50 % of maximum inhibi-
tion. Catalase (E.C.1.11.1.6.) activity was evaluated in 
50 mM phosphate buffer, pH 7.0, with 10 mM hydrogen 
peroxide. One unit of catalase was defined as the amount 
of enzyme needed to degrade 1 μmol H2O2 over 60 s, at 
240  nm. Enzyme activity was analyzed at 25  °C using a 
microplate reader system (μQuant-MQX 200 with KC 
Junior software, Bio-TeK Instruments, Winooski, VT, 
USA). All reagents were purchased from Sigma (St. 
Louis, MO, USA).
Advanced glycation end‑products (AGE) quantification
Paraffin-embedded myocardial tissue was cut, mounted 
on slides for immunohistochemical analysis, and depar-
affinized with EDTA for antigen retrieval [53, 54]. Block-
ade was performed with hydrogen peroxide, goat serum, 
and avidin/biotin. Tissue sections were incubated with 
primary antibody (rabbit polyclonal antibody to AGE; 
Ab23722, Abcam) for 1  h, then with a secondary anti-
body (goat polyclonal secondary antibody to rabbit IgG 
HL—Biotin; Ab6720, Abcam) for 2 h, at room tempera-
ture, and for 15 min with streptavidin. Sections were then 
stained with 3,3′-diaminobenzidine and counterstained 
with hematoxylin [53]. Analysis was performed using a 
video camera coupled to a microscope connected to a 
computer with an image analyzes program (Image Pro 
Plus 6.0, Media Cybernetics, Silver Spring, Maryland, 
USA). Cardiac tissue components were identified accord-
ing to color enhancement. AGEs yield a brown color 
while myocytes are seen in purple. Areas containing 
blood vessels were excluded from this analysis.
NADPH oxidase activity
NADPH oxidase activity was evaluated in membrane-
enriched cellular fraction by quantifying dihydroeth-
idium (DHE) oxidation-derived fluorescent compounds, 
2-hydroxyethidium (EOH) and ethidium, by HPLC 
according to a previously described method [55, 56]. Car-
diac muscle was washed in PBS to remove blood. Muscle 
fragments (∼200 mg) were homogenized in 1 mL of ice-
cold lysis buffer containing 50 mM Tris (pH 7.4), 100 mM 
DTPA, 0.1 % β-mercaptoethanol, and protease inhibitors. 
The samples were then sonicated (3 cycles of 10 s at 8 W) 
and centrifuged at 1000g for 3  min, at 4  °C. The super-
natant was transferred to another microtube and cen-
trifuged at 18,000g for 10  min at 4  °C. The supernatant 
was then centrifuged at 100,000g for 45 min, at 4 °C. The 
supernatant was discarded and the pellet resuspended 
in 100 µL of lysis buffer [56]. Total protein content was 
quantified by the Bradford method. Subsequently, 20 µg 
of membrane-enriched cellular fraction was incubated in 
phosphate buffer (50 mM, pH 7.4, with 0.1 mM DTPA) 
containing DHE (50  µM) and NADPH (300  µM), to a 
final volume of 100 µL, for 30 min at 37  °C in the dark. 
After adding 40 µL of 10 % trichloroacetic acid, the sam-
ples were ice-cooled for 10  min in the dark, and cen-
trifuged at 12,000g for 10  min at 4  °C. The supernatant 
was analyzed by HPLC and the fluorescent DHE-derived 
products were quantified, as previously described [55, 
56].
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Statistical analysis
Results are expressed as mean and standard deviation or 
median and 25th and 75th percentiles according to nor-
mal or non-normal distribution, respectively. Variables 
were compared by two-factor ANOVA followed by the 
Tukey test for normal distribution data or the Dunn test 
for non-normal distribution data. All rats were subjected 
to functional studies as their parameters usually present 
an elevated variability. In papillary muscle preparations, 
some animals were discarded due to technical problems. 
For all morphological and molecular analyzes, sam-
ples were randomly chosen. Statistical significance was 
accepted at p < 0.05.
Results
Initial and final body weight, heart rate, systolic blood 
pressure, and blood glucose are shown in Table 1. Among 
streptozotocin injected rats, 27.5 % did not develop dia-
betes, and were excluded from the study. At the end of 
protocol both diabetic groups presented lower body 
weight and higher glycemia compared to the respective 
control groups; apocynin administration did not change 
body weight, heart rate or glycemia. Initial and final 
blood pressure did not differ between groups.
At the beginning of the protocol, all echocardiographic 
variables were similar between groups (data not shown). 
Echocardiographic structural data assessed at the end 
of the protocol (Table  2) showed higher normalized LV 
diastolic diameter and left atrium diameter in both dia-
betic compared to normoglycemic groups. LV mass-
to-body weight ratio was higher in SHR-DM than SHR, 
and LV posterior wall thickness was lower in SHR-DM-
APO than SHR-APO. LV functional parameters are pre-
sented in Table 3. Systolic function did not differ between 
groups. Isovolumetric relaxation time was higher in dia-
betic groups, indicating diastolic dysfunction.
Data from LV papillary muscle function at basal condi-
tion are shown in Table 4. Apocynin decreased developed 
tension only in non-diabetic rats. The +dT/dt and −dT/
dt were lower and time to peak tension higher in both 
diabetic groups independently of apocynin treatment. 
Results from positive inotropic stimulation are shown in 
Table 5. In 30 s post-rest contraction, developed tension 
and +dT/dt were lower in SHR-APO than SHR. After 
all inotropic stimulation, −dT/dt was lower and time to 
peak tension higher in both diabetic groups than their 
respective controls, and +dT/dt was lower in SHR-DM 
than SHR. SHR-DM-APO did not differ from SHR-DM, 
except by −dT/dt which was lower in SHR-DM-APO 
during 30 s post-rest contraction.
Myocyte diameter did not differ between groups 
(Table 6). Regarding the extracellular matrix, left ventric-
ular myocardial hydroxyproline concentration was higher 
in SHR-DM than SHR and interstitial collagen fraction 
was higher in SHR-DM-APO than SHR-APO. Specifi-
cally, type III collagen expression was lower in both dia-
betic groups (Table 7).
Oxidative stress parameters are shown in Fig. 1. Lipid 
hydroperoxide concentration was higher in SHR-DM 
than SHR and SHR-DM-APO. Glutathione peroxidase 
activity was lower in SHR-APO and SHR-DM than SHR 
and higher in SHR-DM-APO than SHR-DM. NADPH 
oxidase activity and advanced glycation end-products did 
not differ between groups Table 8.  
Discussion
In this study we evaluated the influence of anti-oxidant 
apocynin on cardiac remodeling in spontaneously hyper-
tensive rats with type 1 diabetes mellitus
SHR has extensively been used to evaluate long-term 
pressure overload-induced cardiac remodeling [48]. 
At 1  month old, arterial hypertension starts to increase 
Table 1 Initial and final body weight, heart rate, systolic blood pressure, and blood glucose
Data are expressed as mean ± standard deviation or median and 25th and 75th percentiles
SHR spontaneously hypertensive rats; SHR-APO SHR treated with apocynin; SHR-DM diabetic SHR; SHR-DM-APO diabetic SHR treated with apocynin; BW body weight; 
bpm beats per min; BP systolic blood pressure
Two-factor ANOVA; * p < 0.05 vs SHR; # p < 0.05 vs SHR-APO
SHR (n = 16) SHR‑APO (n = 16) SHR‑DM (n = 13) SHR‑DM‑APO (n = 14)
Initial BW (g) 360 ± 27 361 ± 28 356 ± 16 359 ± 18
Final BW (g) 362 ± 25 364 ± 27 254 ± 36* 239 ± 37#
Initial heart rate (bpm) 294 ± 40.4 304 ± 46.7 308 ± 50.8 304 ± 46.7
Final heart rate (bpm) 269 ± 48.3 287 ± 45.0 255 ± 38.5 249 ± 35.9#
Initial BP (mm Hg) 189 ± 19 189 ± 18 191 ± 18 190 ± 17
Final BP (mm Hg) 184 ± 22 186 ± 21 187 ± 28 184 ± 25
Initial glucose mg/dL) 90 (83–101) 93 (83–100) 91 (90–100) 94 (90–99)
Final glucose (mg/dL) 93 (88–101) 94 (88–107) 600 (542–600)* 600 (538–600)#
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stimulating left ventricular hypertrophy, which remains 
functionally stable until 18–22  months of age [57, 58]. 
Therefore, in this study we evaluated seven-month-old 
rats as they had already developed arterial hypertension 
and stable left ventricular hypertrophy.
Diabetes was caused by streptozotocin, which has been 
widely used to induce type 1 diabetes mellitus in rodents 
[59–61]. Rats with streptozotocin-induced DM can 
develop several diabetic complications, such as neuropa-
thy, nephropathy, and atherosclerosis [37]. The models 
are used not only to study pathological consequences of 
DM, but also to evaluate experimental approaches for the 
treatment of this condition [37]. As previously reported 
[61–63], streptozotocin-induced diabetes mellitus is 
characterized by body weight loss and increased blood 
glucose. Despite the lower final body weight in diabetic 
Table 2 Echocardiographic structural data
Data are expressed as mean ± standard deviation
SHR spontaneously hypertensive rats; SHR-APO SHR treated with apocynin; SHR-DM diabetic SHR; SHR-DM-APO diabetic SHR treated with apocynin; LVDD left 
ventricular (LV) diastolic diameter; BW body weight; LA left atrial diameter; PWT LV posterior wall thickness; RWT relative wall thickness; LVM LV mass
Two-factor ANOVA; * p < 0.05 vs SHR; # p < 0.05 vs SHR-APO
SHR (n = 16) SHR‑APO (n = 16) SHR‑DM (n = 13) SHR‑DM‑APO (n = 14)
LVDD/BW (mm/kg) 19.5 ± 1.87 20.4 ± 2.27 26.2 ± 5.04* 26.6 ± 4.71#
LA/BW (mm/kg) 17.3 ± 2.06 17.3 ± 2.14 20.5 ± 3.97* 21.1 ± 3.23#
PWT (mm) 1.69 ± 0.17 1.71 ± 0.19 1.63 ± 0.17 1.55 ± 0.16#
RWT 0.46 ± 0.06 0.45 ± 0.07 0.47 ± 0.07 0.46 ± 0.07
LVM/BW (g/kg) 2.34 ± 0.37 2.54 ± 0.57 2.89 ± 0.64* 2.70 ± 0.59
Table 3 Echocardiographic left ventricular functional data
Data are expressed as mean ± standard deviation or median and 25th and 75th percentiles
SHR spontaneously hypertensive rats; SHR-APO SHR treated with apocynin; SHR-DM diabetic SHR; SHR-DM-APO diabetic SHR treated with apocynin; MFS midwall 
fractional shortening; TDI S’ tissue Doppler imaging (TDI) of mitral annulus systolic velocity; E/A ratio between early (E)-to-late (A) diastolic mitral inflow; IVRT 
isovolumic relaxation time; E’ TDI of early mitral annulus diastolic velocity
Two-factor ANOVA; * p < 0.05 vs SHR; # p < 0.05 vs SHR-APO
SHR (n = 16) SHR‑APO (n = 16) SHR‑DM (n = 13) SHR‑DM‑APO (n = 14)
MFS (%) 25.9 ± 3.02 25.1 ± 3.53 25.8 ± 2.36 26.3 ± 3.05
TDI S’ (average, cm/s) 3.25 (2.63–3.38) 2.75 (2.50–3.19) 3.00 (2.75–3.00) 2.75 (2.50–3.00)
Tei index 0.61 ± 0.09 0.61 ± 0.12 0.60 ± 0.09 0.61 ± 0.12
E/A 1.72 ± 0.56 1.64 ± 0.58 1.38 ± 0.45 1.70 ± 0.38
IVRT (ms) 31.9 ± 3.12 32.9 ± 5.05 37.2 ± 4.00* 38.9 ± 5.57#
E/E’ 23.3 ± 4.65 24.3 ± 5.03 23.6 ± 4.19 24.1 ± 5.99
Table 4 LV papillary muscle data
Data are expressed as mean ± standard deviation
SHR spontaneously hypertensive rats; SHR-APO SHR treated with apocynin; SHR-DM diabetic SHR; SHR-DM-APO diabetic SHR treated with apocynin; DT peak of 
developed tension; RT resting tension; +dT/dt maximum rate of tension development; TPT time to peak tension; −dT/dt maximum rate of tension decline; CSA 
papillary muscle cross sectional area
Two-factor ANOVA; * p < 0.05 vs SHR; # p < 0.05 vs SHR-APO
SHR (n = 13) SHR‑APO (n = 11) SHR‑DM (n = 11) SHR‑DM‑APO (n = 10)
DT (g/mm2) 11.2 ± 2.37 9.22 ± 1.35* 10.5 ± 2.65 9.17 ± 2.52
RT (g/mm2) 1.06 ± 0.29 1.09 ± 0.30 1.10 ± 0.40 1.11 ± 0.63
+dT/dt (g/mm2/s) 112 ± 24.9 96.2 ± 18.2 92.4 ± 23.1* 85.0 ± 24.2#
TPT (ms) 203 ± 18.4 189 ± 14.5 235 ± 18.6* 227 ± 17.7#
−dT/dt (g/mm2/s) 40.6 ± 10.1 35.1 ± 5.05 33.3 ± 8.92* 27.5 ± 8.31#
CSA (mm2) 0.71 ± 0.13 0.78 ± 0,12 0.72 ± 0.11 0.75 ± 0.14
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rats, blood pressure did not differ between groups. This 
result is in accordance with previous studies on diabetic 
SHR [5, 8]. Therefore, we can discard blood pressure 
changes participating in the cardiac alterations observed 
in our diabetic SHR. In experimental studies, apocynin 
has been used in various dosages, ranging from 4 [32] 
to 100  mg/kg/day [64, 65]. However, moderate apoc-
ynin doses, as administered to our rats (16  mg/kg/day), 
have often been used in rodents [31, 66]. In this study, 
as in previous reports, apocynin did not modulate body 
Table 5 Isolated papillary muscle data after positive inotropic stimulation
Data are expressed as mean ± standard deviation or median and 25th and 75th percentile
SHR spontaneously hypertensive rats; SHR-APO SHR treated with apocynin; SHR-DM diabetic SHR; SHR-DM-APO diabetic SHR treated with apocynin; PP30 30 s post-
rest contraction; 2.5 mM [Ca+2]0 extracellular Ca
2+ concentration increased to 2.5 mM; Iso 10−6 M β-adrenergic agonist isoproterenol (10−6 M) added to the nutrient 
solution; DT peak of developed tension (g/mm2); RT resting tension (g/mm2); +dT/dt maximum rate of tension development (g/mm2/s); TPT time to peak tension (ms); 
−dT/dt maximum rate of tension decline (g/mm2/s)
Two-factor ANOVA; * p < 0.05 vs SHR; # p < 0.05 vs SHR-APO; § p < 0.05 vs SHR-DM
SHR (n = 13) SHR‑APO (n = 11) SHR‑DM (n = 11) SHR‑DM‑APO (n = 10)
PP30 DT 13.7 ± 3.09 11.1 ± 1.69* 11.9 ± 3.01 10.3 ± 2.87
RT 1.04 ± 0.30 1.06 ± 0.31 1.24 ± 0.52 1.25 ± 0.62
+dT/dt 140 ± 33.4 115 ± 23.1* 105 ± 25.0* 95.2 ± 27.8
TPT 215 ± 17.1 209 ± 13.0 255 ± 27.0* 250 ± 22.6#
−dT/dt 42.6 ± 9.67 35.8 ± 4.58 32.4 ± 8.73* 25.1 ± 8.45#§
2.5 mM [Ca+2]0 DT 12.5 ± 2.78 10.3 ± 1.49 11.0 ± 2.95 9.79 ± 2.85
RT 0.87 ± 0.30 0.90 ± 0.31 0.90 ± 0.34 0.92 ± 0.52
+dT/dt 140 ± 31.9 117 ± 21.4 108 ± 28.0* 97.9 ± 28.7
TPT 192 ± 16.9 186 ± 17.8 224 ± 23.2* 216 ± 15.1#
−dT/dt 48.3 ± 10.6 40.0 ± 6.27 38.4 ± 11.6* 30.7 ± 10.2#
Iso 10−6 M DT 11.4 (8.33–13.5) 9.70 (8.77–10.1) 9.68 (8.60–10.1) 9.47 (6.08–10.8)
RT 0.85 ± 0.43 0.86 ± 0.34 0.84 ± 0.28 0.83 ± 0.52
+dT/dt 136 ± 34.0 118 ± 22.4 96.9 ± 26.6* 96.7 ± 31.7
TPT 163 ± 11.1 157 ± 9.49 184 ± 16.9* 190 ± 15.8#
−dT/dt 67.9 ± 16.6 58.3 ± 8.03 46.4 ± 13.4* 39.1 ± 13.7#
Table 6 Left ventricular morphometric parameters and hydroxyproline concentration
Data are expressed as mean ± standard deviation or median and 25th and 75th percentile
SHR spontaneously hypertensive rats; SHR-APO SHR treated with apocynin; SHR-DM diabetic SHR; SHR-DM-APO diabetic SHR treated with apocynin; Diameter myocyte 
lower diameter; HOP myocardial hydroxyproline concentration; ICF myocardial interstitial collagen fraction
Two-factor ANOVA; * p < 0.05 vs SHR; # p < 0.05 vs SHR-APO
SHR (n = 10) SHR‑APO (n = 10) SHR‑DM (n = 10) SHR‑DM‑APO (n = 10)
Diameter (μm) 11.1 (10.3–12.1) 10.3 (10.3–12.2) 10.2 (10.1–12.1) 10.6 (9.88–11.0)
ICF (%) 6.95 ± 2.57 5.47 ± 2.41 9.93 ± 3.59 9.47 ± 4.30#
HOP (mg/g) 2.66 ± 0.29 3.08 ± 0.58 3.27 ± 0.45* 3.29 ± 0.51
Table 7 Left ventricular myocardial protein expression
Data are expressed as mean ± standard deviation
SHR spontaneously hypertensive rats; SHR-APO SHR treated with apocynin; SHR-DM diabetic SHR; SHR-DM-APO diabetic SHR treated with apocynin
Two-factor ANOVA; * p < 0.05 vs SHR; # p < 0.05 vs SHR-APO
SHR (n = 7) SHR‑APO (n = 7) SHR‑DM (n = 7) SHR‑DM‑APO (n = 7)
Type I collagen 1.00 ± 0.41 1.08 ± 0.33 0.99 ± 0.28 0.96 ± 0.14
Type III collagen 1.00 ± 0.10 0.97 ± 0.11 0.77 ± 0.17* 0.83 ± 0.10#
Type I/III collagen ratio 1.00 ± 0.37 1.16 ± 0.42 1.33 ± 0.33 1.15 ± 0.13
Lysyl oxidase 1.00 ± 0.19 0.91 ± 0.15 0.90 ± 0.20 0.89 ± 0.13
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weight, glycemia levels or systemic blood pressure [31, 
32, 67, 68].
In this study, diabetic cardiomyopathy was characterized 
by left chambers dilation, LV mass increase, and diastolic 
dysfunction in SHR. Myocardial functional changes in 
SHR-DM included impaired systolic and diastolic function, 
characterized by a decreased maximum tension develop-
ment rate and maximum tension decline rate and increased 
time to peak tension at basal contraction and after all posi-
tive inotropic stimulation. Similar structural and functional 
cardiac alterations have been described in normotensive 
and hypertensive diabetic rats [5, 18, 69–71]. Cardiac func-
tion in elderly SHR was more extensively jeopardized by 
diabetes than in this study with younger SHR [5].
As potential mechanisms involved in cardiac dilation 
and dysfunction, we observed that SHR-DM had increased 
oxidative stress, characterized by higher myocardial lipid 
hydroperoxide concentration, with altered activity of 
anti-oxidant enzymes glutathione peroxidase and cata-
lase. SHR-DM also present higher myocardial fibrosis, as 
shown by the increased myocardial hydroxyproline con-
centration. Hydroxyproline is the main component of the 
collagen molecule and can only be found at small concen-
trations in a limited number of other proteins. Evaluation 
of myocardial fibrosis through hydroxyproline is consid-
ered more precise than histological analyses [49]. Mechan-
ical properties of myocardium are influenced by both the 
content and type of collagen. Fibrillar collagen types I 
Table 8 Left ventricular myocardial oxidative stress
Data are expressed as mean ± standard deviation or median and 25th and 75th percentile
SHR spontaneously hypertensive rats; SHR-APO SHR treated with apocynin; SHR-DM diabetic SHR; SHR-DM-APO diabetic SHR treated with apocynin; AGEs advanced 
glycation end-products (%); DHE dihydroethidium (µM); EOH 2-hydroxyethidium (µM); E ethidium (µM)
Two-factor ANOVA; p > 0.05
SHR (n = 8) SHR‑APO (n = 8) SHR‑DM (n = 8) SHR‑DM‑APO 
(n = 8)
AGEs 2.47 (2.35–4.16) 2.54 (1.90–3.86) 2.61 (1.83–4.16) 2.68 (2.09–4.97)
DHE 39.1 (38.2–39.7) 39.9 (39.0–40.2) 39.5 (37.4–40.6) 39.4 (38.2–40.2)
EOH 39.6 (31.9–47.6) 38.4 (31.7–40.2) 34.5 (22.4–38.0) 33.2 (29.1–40.1)
E 112 (86.6–165) 97.5 (85.9–222) 119 (112–163) 129 (106–164)
Fig. 1 Left ventricular myocardial oxidative stress markers. Lipid hydroperoxide (a), superoxide dismutase (b), glutathione peroxidase (c) and cata‑
lase (d). Data are expressed as mean ± standard deviation. SHR spontaneously hypertensive rats; SHR-APO SHR treated with apocynin; SHR-DM dia‑
betic SHR; SHR-DM-APO diabetic SHR treated with apocynin. Two‑factor ANOVA; *p < 0.05 vs SHR; #p < 0.05 vs SHR‑APO; §p < 0.05 vs SHR‑DM‑APO
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and III are the main components of the cardiac extracel-
lular matrix [72]. Type I collagen is associated with higher 
stiffness in different tissues than type III collagen [73, 74]. 
Alterations in collagen fiber quantities and type have often 
been observed in diabetic cardiomyopathy [69, 75]. There-
fore, in this study, the increased collagen concentration, 
reduced type III collagen expression, and augmented oxi-
dative stress may be involved in the cardiac and myocar-
dial dysfunction observed in SHR-DM.
Apocynin administration did not change cardiac struc-
tures or function in control SHR. However, in papillary 
muscles, apocynin reduced developed tension at basal 
conditions and in post-rest contraction in SHR-APO 
compared to SHR. Despite lower glutathione peroxi-
dase activity in SHR-APO, oxidative stress did not differ 
between SHR-APO and SHR. We can therefore conclude 
that apocynin impaired myocardial function indepen-
dently of changes in oxidative stress. This result was unex-
pected as apocynin displayed beneficial effects in different 
experimental models of cardiac injury. In rodents with 
pressure overload induced by abdominal aorta banding 
[76] or angiotensin II infusion [77], apocynin attenuated 
cardiac hypertrophy, oxidative stress, cardiac fibrosis, and 
diastolic dysfunction. These effects were mediated at least 
in part through a pathway involving NADPH oxidase [77]. 
Also in type 4 cardiorenal syndrome [78] and chronic 
renal failure [79], apocynin attenuated cardiac injury. On 
the other hand, apocynin can exert cytotoxic effects in cell 
cultures [80]. One study recently showed that apocynin 
downregulates Akt activity in mouse embryonic stem 
cells [35]. Also in vascular smooth muscle cells, apocynin 
prevented the activation of Akt by hydrogen peroxide and 
by intracellular radical generator menadione [20]. The Akt 
signaling pathway is involved in myocyte cell surviving 
[81]; it is therefore possible that its inhibition contributed 
to the myocardial impairment seen in SHR-APO. As, to 
the best of our knowledge, this is the first study to evalu-
ate the effects of apocynin on cardiac remodeling in adult 
SHR, we cannot compare our results with literature data.
In diabetic SHR, apocynin reduced oxidative stress, 
evaluated by the myocardial lipid hydroperoxide concen-
tration, and preserved anti-oxidant enzyme activity in 
SHR-DM-APO compared to SHR-DM. Despite the lower 
oxidative stress, LV and myocardial function was not 
changed by apocynin, except for a lower post-rest con-
traction −dT/dt in SHR-DM-APO than SHR-DM. Myo-
cardial fibrosis did not differ from SHR-DM.
Apocynin can be isolated and purified from several 
plant species such as Picrorhiza kurroa, and has been 
evaluated in experimental studies as an anti-oxidant 
agent [82–84]. It has mostly been used as an inhibi-
tor of NADPH oxidase activity [20, 21, 82, 85]. In this 
study, NADPH oxidase activity and AGEs did not differ 
between groups. It is possible that adult SHR already 
have increased basal levels of NADPH oxidase activ-
ity and AGEs [86, 87] which could not be modulated by 
diabetes or apocynin. In fact, 3-month old diabetic SHR 
presented higher cardiac NADPH oxidase activity than 
control SHR [88]. Thus, apocynin reduced myocardial 
oxidative stress in SHR-DM-APO through mechanisms 
not involving NADPH oxidase activity. In cultured cells, 
apocynin acted as a ROS scavenger and not an NADPH 
oxidase inhibitor [20]. Apocynin can also modulate nitric 
oxide-dependent pathways. Apocynin has been shown 
to increase nitric oxide bioavailability through, at least 
partly, induction of nitric oxide synthase [89]. In  vivo 
studies showed that apocynin restored normal flow 
mediated nitric oxide signaling in young SHR arteries 
[90] and increased nitric oxide synthase activity in persis-
tent pulmonary hypertension of the newborn [91]. Addi-
tional studies are needed to clarify the effects of apocynin 
on cardiac remodeling in SHR with and without diabetes.
In conclusion, apocynin reduces oxidative stress 
through unrelated NADPH oxidase activity mechanisms 
and does not change ventricular or myocardial function 
in spontaneously hypertensive rats with type 1 diabetes. 
The apocynin-induced myocardial functional impair-
ment in spontaneously hypertensive rats without diabe-
tes shows that apocynin action during sustained chronic 
pressure overload needs to be clarified.
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